Stock listing

LS Exchange:A4243T Kala Bio, Inc. Aktie

German listing (LS Exchange) of Kala Bio, Inc. · home listing NASDAQ:KALA

Follow Kala Bio, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:KALA

$2.71 USD -0.55 (-17.0%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:KALA

Past year -99.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$2.65 – $3.17 USDNov 20, 2026
Volume
18,551 sharesNov 20, 2026
Market cap
$1.74M USDAt the close on Nov 20, 2026 · price × 644,660 shares outstanding
52-week range
$2.65 – $2,865.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$26,651 USDMedian day 273 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Kala Bio, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:KALA · Home$2.705 USD-0.555 (-17.0%)18,551$3.02$3.17$2.65$3.26Close on Nov 20, 2026
LSE:0JQ2$2.90 USD-0.33 (-10.2%)651$3.30$3.30$2.87$3.23Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:KALA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$2.705-0.555-17.0%$3.02$3.17$2.6518,551
$3.26-0.17-5.0%$3.72$3.72$3.267,946
$3.43-0.40-10.4%$3.50$3.70$3.4211,882
$3.83-0.334-8.0%$3.79$4.033$3.5129,804
$4.164-0.666-13.8%$4.488$4.53$3.961,041
$4.83-0.30-5.8%$5.01$5.118$4.761428
$5.130.000.0%$5.16$5.22$4.98117
$5.13-0.189-3.6%$5.19$5.538$5.067159
$5.319+0.642+13.7%$4.839$5.337$4.839239
$4.677+0.102+2.2%$5.10$5.10$4.536160
$4.575-0.768-14.4%$5.55$5.55$4.50257
$5.343+0.153+2.9%$5.397$5.556$5.16391
$5.19+0.174+3.5%$4.998$5.544$4.989237
$5.016+0.051+1.0%$5.10$5.397$4.989171
$4.965-0.288-5.5%$5.25$5.496$4.89273
$5.253-0.144-2.7%$5.598$5.691$5.25191
$5.397+0.123+2.3%$5.40$5.64$5.25122
$5.274-0.312-5.6%$5.46$5.634$5.133210
$5.586-0.117-2.1%$5.70$5.82$5.49132
$5.703+0.138+2.5%$5.586$6.00$5.553231
$5.565-0.159-2.8%$5.73$5.898$5.463134
$5.724+0.033+0.6%$6.03$6.153$5.463262
$5.691-0.087-1.5%$5.94$6.30$5.574417
$5.778+0.081+1.4%$6.00$6.30$5.70282
$5.697-0.069-1.2%$5.97$5.991$5.463320
$5.766+0.126+2.2%$5.709$6.153$5.16956
$5.64-2.16-27.7%$7.791$7.938$3.4381,853
$7.80-0.60-7.1%$8.55$8.55$7.779474
$8.40-0.42-4.8%$8.553$8.94$8.322423
$8.82-0.078-0.9%$9.048$9.048$8.58317
$8.898-1.902-17.6%$10.44$10.48$8.745736
$10.80-0.12-1.1%$11.19$11.85$10.28727
$10.92+0.045+0.4%$10.50$11.70$10.32467
$10.88-0.675-5.8%$11.61$11.70$10.531,202
$11.55-1.032-8.2%$12.30$12.60$11.411,195
$12.58-0.297-2.3%$12.50$13.76$12.241,802
$12.88-2.22-14.7%$15.76$16.14$12.3132,704
$15.10+1.593+11.8%$12.43$16.20$12.0342,143
$13.51-0.762-5.3%$13.91$14.69$12.94641
$14.27-2.532-15.1%$16.38$16.50$13.94405
$16.800.000.0%$15.93$17.10$15.75771
$16.80-1.17-6.5%$17.45$17.71$16.8092
$17.97+1.17+7.0%$17.10$18.35$16.51152
$16.80+0.63+3.9%$16.98$17.39$16.3057
$16.17-0.768-4.5%$16.49$17.40$15.9391
$16.94+1.29+8.2%$16.77$17.31$16.04138
$15.65+0.417+2.7%$16.05$16.21$15.33194
$15.23-0.99-6.1%$16.40$16.60$15.01201
$16.22-0.951-5.5%$17.40$17.50$16.06203
$17.17+0.285+1.7%$17.76$17.99$17.17124
$16.89+0.186+1.1%$16.80$18.06$16.51344
$16.70+0.564+3.5%$16.01$18.30$15.87594
$16.14+0.918+6.0%$15.60$16.39$14.70195
$15.22-1.611-9.6%$16.35$16.71$15.02290
$16.83+1.155+7.4%$15.81$17.25$15.60642
$15.67-0.291-1.8%$16.05$16.96$15.09490
$15.97-4.215-20.9%$15.62$17.10$15.3010,083
$20.18-0.522-2.5%$20.36$22.80$19.89267
$20.70-3.66-15.0%$24.99$32.79$17.602,685
$24.36-0.12-0.5%$24.03$25.50$24.0336
$24.48-0.147-0.6%$24.30$24.79$24.3068
$24.63+0.768+3.2%$25.20$25.20$23.7024
$23.86-0.741-3.0%$24.60$25.20$23.4563
$24.60-0.60-2.4%$29.52$29.52$24.00112
$25.20-1.797-6.7%$28.17$28.76$24.3072

Splits

3 splits since 2022 · NASDAQ:KALA · every price before a split is adjusted for it

DayRatioWhat
1-for-30Consolidation
1-for-50Consolidation
1-for-50Consolidation
Ticker
LS Exchange:A4243T
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
LS Exchange
Currency
EUR

What changed lately

Latest news

KALA BIO Announces Reverse Stock Split

Nov 12, 2026

Closed $4.83 (-5.8%) on Nov 12, 2026

All Kala Bio, Inc. news

Kala Bio, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
18 in the last 12 months · 114 in all · newest Nov 12, 2026 · oldest 2019
Calls
7 calls with a replay · 7 with a transcript · latest Aug 11, 2022

Where Kala Bio, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:KALA · Home listingNASDAQUnited StatesUSD
gettex:27F0gettexGermanyEUR
LS Exchange:A3DWPSLS ExchangeGermanyEUR
BOATS:KALABOATSUnited StatesUSD
LSE:0JQ2LSEUnited KingdomUSD
Lang & Schwarz:A3DWPSLang & SchwarzGermanyEUR
Tradegate:27FTradegateGermanyEUR
gettex:27FgettexGermanyEUR
Munich:27FMunichGermanyEUR
LS Exchange:A4243T · This pageLS ExchangeGermanyEUR
Frankfurt:27FFrankfurtGermanyEUR
Lang & Schwarz:A4243TLang & SchwarzGermanyEUR

Valuation

Price/book 0.2× against a median of 0.4×: 3rd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
−$5.49M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.2×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
2.76

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Kala Bio, Inc. · NASDAQ:KALAUS$1.74M−US$5.49Mn/an/an/a0.2×n/a0.0×2.76
CASI Pharmaceuticals, Inc. · OTC:CASIFUS$2.06MUS$38.79Mn/a1.9×n/an/a−218.6%n/a-0.07
Vectus Biosystems Limited · ASX:VBSUS$2.02MUS$50,9661.9×n/an/a1.3×n/a0.2×n/a
Decoy Therapeutics Inc. · NASDAQ:DCOYUS$1.98M−US$6.19Mn/a−11.6×n/a0.4×n/a0.0×1.28
Genprex, Inc. · NASDAQ:GNPXUS$1.94M−US$13.41Mn/an/an/a0.1×n/a0.0×1.08
Propanc Biopharma, Inc. · NASDAQ:PPCBUS$1.84MUS$1.62Mn/an/an/a0.3×n/a0.0×1.39
Argent Biopharma Ltd · ASX:RGTUS$1.79MUS$8.05Mn/a75.4×n/an/an/an/an/a
Calidi Biotherapeutics, Inc. · AMEX:CLDIUS$1.76M−US$2.19Mn/an/an/a1.1×n/a0.0×1.86
SOHM, Inc. · OTC:SHMNUS$1.74MUS$4.99Mn/a5.5×n/a0.5×−28.1%0.9×-0.10
PRF Technologies Ltd. · NASDAQ:PRFXUS$1.66M−US$9.82Mn/a−249×n/a0.1×n/a0.0×1.93
Jupiter Neurosciences, Inc. · NASDAQ:JUNSUS$1.63MUS$1.33Mn/a16.9×n/an/an/an/a1.88
Median of the othersUS$1.82MUS$689,3581.9×3.7×0.4×−123.3%0.0×1.34

Forecasts

Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
1.50 USD · Analysts' mean
EPS, year to Dec 2025
-4.45 · 1 analyst

Team and board

OfficerRole
Avi MinkowitzChief Executive Officer and Chief Financial Officer

Events

Calls

CallWhenStatus
KALA BIO (NASDAQ:KALA) Q2 2022 Earnings CallThu, Aug 11, 2022 · 8:00 AM ETReplay
KALA BIO (NASDAQ:KALA) Q1 2022 Earnings CallMon, May 16, 2022 · 8:00 AM ETReplay
KALA BIO (NASDAQ:KALA) Q4 2021 Earnings CallTue, Mar 29, 2022 · 8:00 AM ETReplay
KALA BIO (NASDAQ:KALA) Q3 2021 Earnings CallMon, Nov 15, 2021 · 10:30 AM ETReplay
KALA BIO (NASDAQ:KALA) Q2 2021 Earnings CallThu, Aug 05, 2021 · 8:00 AM ETReplay
KALA BIO (NASDAQ:KALA) Q1 2021 Earnings CallWed, May 05, 2021 · 8:00 AM ETReplay
KALA BIO (NASDAQ:KALA) Q3 2020 Earnings CallThu, Nov 05, 2020 · 8:00 AM ETReplay

Results days

QuarterResultsShare move
Quarter to Sep 30, 2026Nov 18, 2026−21.1%
Q2 2026Aug 19, 2026−6.5%
Q1 2026May 29, 2026−3.9%
Q3 2025Nov 19, 2025 · Before open−8.1%
Q2 2025Aug 8, 2025 · Before open+3.1%
Q1 2025May 14, 2025 · After close−1.5%
Q4 2024Mar 27, 2025 · Before open−3.8%
Q3 2024Nov 12, 2024 · After close−2.0%
Q2 2024Aug 6, 2024 · After close−0.8%
Q1 2024May 14, 2024 · After close−1.6%
All 20 quarters
QuarterResultsShare move
Q4 2023Mar 29, 2024 · Before open+0.3%
Q3 2023Nov 13, 2023 · Before open−0.7%
Q2 2023Aug 4, 2023 · Before open−1.6%
Q1 2023May 9, 2023 · Before open−2.5%
Q4 2022Mar 3, 2023 · Before open+64.7%
Q3 2022Nov 8, 2022 · Before open+0.8%
Q2 2022Aug 11, 2022 · Before open−5.8%
Q1 2022May 16, 2022 · Before open+8.5%
Q4 2021Mar 29, 2022 · Before open−14.3%
Q3 2021Nov 15, 2021 · Before open+1.4%

Open Events

Financings

RaiseDate
Registered direct offering of common stock (or pre-funded warrants in lieu thereof)
Closed: US$10M raised · US$1 a share · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Repay certain indebtedness and general corporate purposes
Dec 5, 2025
Private placement of non-voting convertible preferred stock
Tranche closed: US$1.8M raised
Buyers: David E. Lazar ($6 million of non-voting convertible preferred stock; $1.8 million of Series AA preferred in first closing, $4.2 million of Series AAA preferred in second closing)
Insiders: Investor David E. Lazar was appointed Chief Executive Officer and Chairman of the Board effective immediately.
Use of proceeds: Evaluation and redevelopment of product candidates and patent portfolio, working capital and funding for a potential strategic transaction
Dec 1, 2025
Private placement of common stock and Series I Convertible Non-Redeemable Preferred Stock
Announced: about US$10.75M · US$6.44 a share
Buyers: SR One; Cormorant Asset Management; Woodline Partners
Use of proceeds: Advance clinical development of KPI-012 for persistent corneal epithelial defect and general corporate purposes
Dec 30, 2024

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Kala Pharmaceuticals, Inc. Priced at US$15.00 a share on Jul 19, 2017.

Price
US$15.00 a share
Shares offered
6,000,000 shares of common stock
Offering size
US$90 million
Underwriters' option
Up to 900,000 more shares
Listing
KALA on the Nasdaq Global Select Market
Underwriters
J.P. Morgan, BofA Merrill Lynch, Wells Fargo Securities, Wedbush PacGrow · In the order on the cover
Shares delivered
On or about Jul 25, 2017

Steps

StepWhen
Draft sent to the SEC in confidenceSep 21, 2015
Filed publiclyJun 23, 2017
Amended onceJul 10, 2017
Shares registered with an exchangeJul 14, 2017
Declared effective by the SECJul 19, 2017
Final prospectus, with the priceJul 20, 2017

Open IPO · From the cover of the final prospectus (424B4) filed Jul 20, 2017

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0003.89M11.2M6.36M6.07M000
Cost of revenue317.0K259.0K303.0K2.56M4.10M3.17M2.85M955.0K643.0K297.0K
Gross profit-317.0K-259.0K-303.0K1.33M7.14M3.19M3.23M-955.0K-643.0K-297.0K
Research and development18.8M22.1M18.6M17.7M11.5M18.4M27.3M29.3M29.0M25.0M
Selling, general and administrative23.6M18.3M20.6M65.0M105.1M81.1M65.0M35.4M10.9M7.64M
Operating income-39.2M-41.0M-39.7M-81.7M-130.2M-96.2M-88.2M-64.7M-39.9M-32.7M
Depreciation and amortization317.0K259.0K303.0K537.0K975.0K912.0K843.0K352.0K287.0K297.0K
EBITDA-38.8M-40.7M-39.4M-81.2M-129.3M-95.3M-87.4M-64.4M-39.6M-32.4M
Interest expense3.28M5.78M5.81M7.27M8.38M8.59M8.48M3.31M1.02M767.0K
Income before tax-27.0M-38.5M-42.2M-44.8M-142.6M-104.3M-94.3M-66.7M-42.2M-33.2M
Income tax0000000000
Net income-27.0M-38.5M-42.2M-44.8M-142.6M-104.3M-94.3M-66.7M-42.2M-33.2M
Earnings per share, basic-3.31-10.15-17.35-29.48-108.32-1.99-2.76-2.49-3.71-28.07
Earnings per share, diluted-3.31-10.15-17.35-29.48-108.32-1.99-2.76-2.49-3.71-28.07

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents7.56M51.2M50.9M70.5M92.1M77.3M85.4M170.9M114.6M45.5M
Short-term investments076.3M699.0K0
Receivables236.0K195.0K15.3M9.60M11.6M1.03M
Inventory7.67M8.64M5.23M4.65M4.09M0
Current assets9.49M52.8M52.9M85.9M124.4M171.4M105.5M177.0M115.2M45.6M
Property, plant and equipment749.0K753.0K400.0K2.72M3.17M2.70M2.17M786.0K594.0K
Goodwill0
Total assets9.49M55.5M55.9M86.8M139.4M221.6M154.3M221.0M116.5M46.3M
Accounts payable986.0K628.0K919.0K2.83M4.90M1.72M2.52M5.45M1.20M997.0K
Current liabilities2.49M17.0M8.35M25.7M37.4M22.2M24.8M17.0M14.9M5.55M
Long-term debt20.1M34.2M37.9M78.9M72.2M71.2M70.2M12.0M9.10M
Total debt29.3M34.0M43.3M80.0M75.0M75.0M75.0M18.9M9.65M
Total liabilities2.49M43.2M48.4M67.8M122.6M121.6M124.6M116.0M26.9M15.7M
Shareholders' equity7.00M12.3M7.50M19.0M16.8M100.0M29.7M105.0M89.7M-87.8M
Shares outstanding557.0K6.09M2.76M1.71M1.32M58.9M36.1M33.9M24.5M1.18M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-32.0M-29.4M-27.9M-78.9M-108.2M-90.7M-92.7M-54.1M-34.1M-27.3M
Capital spending-15.0K-208.0K-610.0K-313.0K-886.0K-1.94M-1.33M-1.58M-480.0K-153.0K
Free cash flow-32.0M-29.6M-28.5M-79.2M-109.1M-92.6M-94.1M-55.7M-34.6M-27.5M
Cash from investing-15.0K-208.0K-429.0K62.7M70.8M-78.2M-1.33M-1.58M-480.0K-153.0K
Cash from financing-11.6M29.9M8.51M-7.94M42.6M160.6M8.98M124.1M103.7M67.2M
Dividends paid-365.0K0
Share buybacks365.0K1.58M160.7M9.01M71.3M97.1M67.9M
Change in cash-43.6M286.0K-19.9M-24.1M5.12M-8.28M-85.1M68.4M69.1M39.7M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 16, 2026Current reportSEC
NT 10-Q · Late filing noticeNov 13, 2026Explanation requestSEC
8-K · Current reportNov 12, 2026Current reportSEC
8-K · Current reportNov 9, 2026ResultsSEC
8-K · Current reportNov 3, 2026Meeting outcomeSEC
SCHEDULE 13G · Big-stake noticeOct 19, 2026Big-stake noticeSEC
DEF 14A · Proxy statementSep 24, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementSep 11, 2026Meeting noticeSEC
8-K · Current reportSep 10, 2026Material contractSEC
8-K · Current reportSep 9, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportAug 28, 2026Current reportSEC
10-Q · Quarterly reportAug 19, 2026Quarterly reportSEC
NT 10-Q · Late filing noticeAug 14, 2026Explanation requestSEC
8-K · Current reportJul 22, 2026Current reportSEC
424B5 · ProspectusJul 22, 2026Offer documentSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 2, 2026Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveJun 26, 2026Other filingsSEC
S-3/A · Registration statement, amendedJun 12, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
S-3 · Registration statementMay 7, 2026Offer documentSEC
8-K · Current reportMay 7, 2026Current reportSEC
10-K · Annual reportApr 15, 2026Annual reportSEC
NT 10-K · Late filing noticeMar 31, 2026Explanation requestSEC
DMar 17, 2026Other filingsSEC
144 · Notice of proposed saleMar 17, 2026Other filingsSEC
144 · Notice of proposed saleMar 12, 2026Other filingsSEC
144 · Notice of proposed saleMar 12, 2026Other filingsSEC
8-K · Current reportMar 4, 2026Material contractSEC
8-K · Current reportFeb 20, 2026Management or board changeSEC
EFFECT · Notice that a registration is effectiveFeb 18, 2026Other filingsSEC
424B3 · ProspectusFeb 17, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
CORRESP · Letter to the SECFeb 13, 2026Other filingsSEC
UPLOAD · Letter from the SECFeb 13, 2026Other filingsSEC
DFeb 12, 2026Other filingsSEC
S-3 · Registration statementFeb 9, 2026Offer documentSEC
3 · Initial statement of ownershipFeb 9, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 9, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 9, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 9, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 9, 2026Insider tradeSEC
SCHEDULE 13D · Big-stake noticeFeb 6, 2026Big-stake noticeSEC
8-K · Current reportFeb 5, 2026Management or board changeSEC
8-K · Current reportFeb 2, 2026Material contractSEC
DEFA14A · Additional proxy materialJan 26, 2026Meeting noticeSEC
8-K · Current reportJan 23, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeJan 13, 2026Big-stake noticeSEC
8-K · Current reportJan 8, 2026Material contractSEC
424B5 · ProspectusJan 8, 2026Offer documentSEC
DEFA14A · Additional proxy materialJan 6, 2026Meeting noticeSEC
8-K · Current reportJan 6, 2026Material contractSEC
8-K · Current reportJan 2, 2026Current reportSEC
DEF 14A · Proxy statementDec 30, 2025Meeting noticeSEC
8-K · Current reportDec 29, 2025Management or board changeSEC
4 · Change in ownershipDec 22, 2025Insider tradeSEC
PRER14ADec 19, 2025Other filingsSEC
8-K · Current reportDec 16, 2025Current reportSEC
8-K · Current reportDec 16, 2025Current reportSEC
8-K · Current reportDec 5, 2025Material contractSEC
424B5 · ProspectusDec 5, 2025Offer documentSEC
3 · Initial statement of ownershipDec 3, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeDec 3, 2025Big-stake noticeSEC
3/A · Initial statement of ownership, amendedDec 2, 2025Insider tradeSEC
4 · Change in ownershipNov 26, 2025Insider tradeSEC
3 · Initial statement of ownershipNov 26, 2025Insider tradeSEC
8-K · Current reportNov 25, 2025Material contractSEC
10-Q · Quarterly reportNov 19, 2025Quarterly reportSEC
NT 10-Q · Late filing noticeNov 14, 2025Explanation requestSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
8-K · Current reportNov 12, 2025Current reportSEC
8-K · Current reportNov 10, 2025Material contractSEC
4 · Change in ownershipOct 24, 2025Insider tradeSEC
4 · Change in ownershipOct 24, 2025Insider tradeSEC
4 · Change in ownershipOct 24, 2025Insider tradeSEC
4 · Change in ownershipOct 24, 2025Insider tradeSEC
4 · Change in ownershipOct 24, 2025Insider tradeSEC
144 · Notice of proposed saleOct 23, 2025Other filingsSEC
144 · Notice of proposed saleOct 23, 2025Other filingsSEC
144 · Notice of proposed saleOct 22, 2025Other filingsSEC
144 · Notice of proposed saleOct 22, 2025Other filingsSEC
144 · Notice of proposed saleOct 22, 2025Other filingsSEC
144 · Notice of proposed saleOct 22, 2025Other filingsSEC
8-K · Current reportOct 20, 2025Management or board changeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 15, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 3, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 2, 2025Big-stake noticeSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
8-K/A · Current report, amendedOct 2, 2025Management or board changeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 1, 2025Big-stake noticeSEC
8-K · Current reportOct 1, 2025Current reportSEC
8-K · Current reportSep 29, 2025Current reportSEC
8-K · Current reportSep 18, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeSep 11, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeSep 11, 2025Big-stake noticeSEC
4 · Change in ownershipSep 2, 2025Insider tradeSEC
8-K · Current reportSep 2, 2025Management or board changeSEC
10-Q · Quarterly reportAug 8, 2025Quarterly reportSEC
8-K · Current reportAug 8, 2025ResultsSEC
8-K · Current reportJul 9, 2025Current reportSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
144 · Notice of proposed saleJun 24, 2025Other filingsSEC
144 · Notice of proposed saleJun 24, 2025Other filingsSEC
144 · Notice of proposed saleJun 24, 2025Other filingsSEC
144 · Notice of proposed saleJun 24, 2025Other filingsSEC
144 · Notice of proposed saleJun 24, 2025Other filingsSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
4/A · Change in ownership, amendedJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
144 · Notice of proposed saleJun 3, 2025Other filingsSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
8-K · Current reportMay 14, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2025Big-stake noticeSEC
8-K · Current reportApr 11, 2025Management or board changeSEC
424B5 · ProspectusMar 31, 2025Offer documentSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
8-K · Current reportMar 31, 2025ResultsSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
8-K · Current reportFeb 12, 2025Management or board changeSEC
EFFECT · Notice that a registration is effectiveFeb 5, 2025Other filingsSEC
424B3 · ProspectusFeb 4, 2025Offer documentSEC
CORRESP · Letter to the SECJan 31, 2025Other filingsSEC
UPLOAD · Letter from the SECJan 31, 2025Other filingsSEC
S-3 · Registration statementJan 24, 2025Offer documentSEC
4/A · Change in ownership, amendedJan 10, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
144 · Notice of proposed saleJan 6, 2025Other filingsSEC
S-8 · Registration statement for employee plansJan 3, 2025Offer documentSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 31, 2024Big-stake noticeSEC
DDec 31, 2024Other filingsSEC
4 · Change in ownershipDec 31, 2024Insider tradeSEC
8-K · Current reportDec 30, 2024Material contractSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
8-K · Current reportSep 25, 2024Management or board changeSEC
424B5 · ProspectusSep 6, 2024Offer documentSEC
10-Q · Quarterly reportAug 6, 2024Quarterly reportSEC
8-K · Current reportAug 6, 2024ResultsSEC
EFFECT · Notice that a registration is effectiveAug 1, 2024Other filingsSEC
424B3 · ProspectusJul 31, 2024Offer documentSEC
CORRESP · Letter to the SECJul 29, 2024Other filingsSEC
UPLOAD · Letter from the SECJul 26, 2024Other filingsSEC
S-3 · Registration statementJul 25, 2024Offer documentSEC
144 · Notice of proposed saleJul 17, 2024Other filingsSEC
144 · Notice of proposed saleJul 16, 2024Other filingsSEC
SC 13D · Big-stake noticeJul 8, 2024Big-stake noticeSEC
DJun 28, 2024Other filingsSEC
SC 13D · Big-stake noticeJun 28, 2024Big-stake noticeSEC
3 · Initial statement of ownershipJun 28, 2024Insider tradeSEC
4 · Change in ownershipJun 27, 2024Insider tradeSEC
4 · Change in ownershipJun 27, 2024Insider tradeSEC
4 · Change in ownershipJun 27, 2024Insider tradeSEC
4 · Change in ownershipJun 27, 2024Insider tradeSEC
4 · Change in ownershipJun 27, 2024Insider tradeSEC
8-K · Current reportJun 27, 2024Material contractSEC
144 · Notice of proposed saleJun 24, 2024Other filingsSEC
144 · Notice of proposed saleJun 24, 2024Other filingsSEC
144 · Notice of proposed saleJun 24, 2024Other filingsSEC
144 · Notice of proposed saleJun 24, 2024Other filingsSEC
144 · Notice of proposed saleJun 24, 2024Other filingsSEC
4 · Change in ownershipJun 12, 2024Insider tradeSEC
4 · Change in ownershipJun 12, 2024Insider tradeSEC
4 · Change in ownershipJun 12, 2024Insider tradeSEC
4 · Change in ownershipJun 12, 2024Insider tradeSEC
4 · Change in ownershipJun 12, 2024Insider tradeSEC
4 · Change in ownershipJun 12, 2024Insider tradeSEC
8-K · Current reportJun 12, 2024Meeting outcomeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
144 · Notice of proposed saleMay 31, 2024Other filingsSEC
DEFA14A · Additional proxy materialMay 30, 2024Meeting noticeSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
8-K · Current reportMay 14, 2024ResultsSEC
ARS · Annual report to shareholdersApr 29, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2024Meeting noticeSEC

This page holds 200 of 679 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Kala Bio, Inc.’s releases · as of Nov 16, 2026

Common shares
644,660
Fully diluted
644,660

Fully diluted

LineSharesAs of
Common shares644,660Nov 16, 2026

Share count over time

CountShares
Nov 16, 2026644,660
Nov 16, 2026
Nov 12, 2026

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
Vanguard322K1.7%US$138KNo changeNov 13, 2026
Geode Capital174K0.90%US$74,675+28,796Nov 6, 2026
State Street88,5700.46%US$38,023NewNov 12, 2026
Renaissance Technologies81,1000.42%US$34,816NewNov 12, 2026
Susquehanna79,8310.41%US$34,271NewNov 16, 2026
BlackRock71,4460.37%US$30,671−96Nov 13, 2026
Northern Trust41,6060.22%US$17,861No changeNov 16, 2026
UBS1,345<0.01%US$577−7,712Nov 10, 2026
Morgan Stanley124<0.01%US$54+96Nov 13, 2026
Tower Research Capital LLC (TRC)45<0.01%US$19−571Nov 16, 2026
All 15 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
Bank Julius Baer & Co. Ltd, Zurich5<0.01%NewOct 29, 2026
Berthel, Fisher & Company Financial Services, Inc.3<0.01%US$1NewNov 13, 2026
Northwestern Mutual Wealth Management Co1<0.01%NewNov 13, 2026
Barclays1<0.01%−607Nov 6, 2026
Caitong International Asset Management Co., Ltd1<0.01%−9Oct 29, 2026

Funds

HolderSharesOf the companyValueChangeAs of
Vanguard Extended Market Index Fund221K1.1%US$382K+160KJun 30, 2026
Fidelity Nasdaq Composite Index Fund5,6330.03%US$12,562−795May 31, 2026
Fidelity Extended Market Index Fund3,8220.02%US$8,523−36,328May 31, 2026
Total Stock Market Index Trust355<0.01%US$614−388Jun 30, 2026
Fidelity Total Market Index Fund236<0.01%US$526−11,569May 31, 2026
Fidelity Series Total Market Index Fund152<0.01%US$339−7,493May 31, 2026

Big stakes

HolderStakeSharesDate
OXFORD FINANCE LLC16.50%1.62MNov 25, 2025
LifeSci Capital LLC7.90%2.2MDec 30, 2025
Labkowski Nachum5.00%967KOct 14, 2026
SR One Capital Management, LLC4.60%344KOct 14, 2025
Lazar David E.3.90%719KMay 20, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Peter Kolchinsky
Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Wave Life Sciences Ltd. (Director · Since at least Aug 14, 2015); Black Diamond Therapeutics, Inc. (Director · Jul 5, 2023 – Jul 5, 2023 · Past); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Research Alliance Corp II (Chief Executive Officer, Director · Mar 17, 2021 – Mar 17, 2021 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Solid Biosciences Inc. (Director · Dec 10, 2020 – Jan 11, 2024 · Past); POINT Biopharma Global Inc (Chief Executive Officer, Director · Jul 7, 2020 – Jun 29, 2021 · Past); Forma Therapeutics Holdings Inc (Director · Jun 18, 2020 – Jun 8, 2022 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 3, 2022 · Past); Synthorx Inc (Director · Dec 6, 2018 – Jan 23, 2020 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – Jun 19, 2018 · Past); KalVista Pharmaceuticals, Inc. (Director · Oct 12, 2017 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Jun 20, 2017 – Apr 2, 2020 · Past); Dicerna Pharmaceuticals Inc (Director · Jan 29, 2014 – Nov 27, 2019 · Past)
Director · Oct 3, 2018 – Mar 13, 2020 · Past
Rajeev M Shah
Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past)
Director · Jul 19, 2017 – Jun 17, 2021 · Past
David Lazar
Other companies: Aterian, Inc. (Chair of the Board · Since at least Apr 27, 2026); Quantum Cyber N.V. (CEO · Since at least Feb 13, 2026); Sow Good Inc. (Chief Executive Officer and Chair of the Board · Since at least Dec 31, 2025); Indaptus Therapeutics, Inc. (Director · Since at least Dec 22, 2025); Stablecoin Development Corporation (Chief Executive Officer, Director · Since at least Aug 19, 2025); Bio Green Med Solution, Inc. (Interim CEO · Jan 2, 2025 – Feb 26, 2025 · Past); LQR House Inc. (President, Director · Oct 15, 2024 – Apr 2, 2025 · Past); CapForce Inc. (Chief Executive Officer, Director · Mar 25, 2024 – Jul 30, 2024 · Past); FiEE, Inc (Director · Dec 29, 2023 – Feb 18, 2025 · Past); Titan Pharmaceuticals Inc (Chief Executive Officer, Director · Jan 24, 2023 – Jul 26, 2023 · Past)
Chief Executive Officer, Director · Since at least Nov 23, 2025
Andrew Koven
Other companies: MetaVia Inc. (Chairman of the Board · Since at least Jul 9, 2021); Aralez Pharmaceuticals Inc (President & Chief Business Off · Feb 5, 2016 – Jun 4, 2018 · Past); POZEN Inc (President, Chief Business Ofc. · May 31, 2015 – Jun 3, 2015 · Past); Auxilium Pharmaceuticals Inc (EVP, CAO, GC and Secretary · Feb 3, 2012 – Jan 29, 2015 · Past); Inspire Pharmaceuticals Inc (EVP & Chief Admin & Legal Ofc · May 10, 2010 – May 13, 2011 · Past); Sepracor Inc (Exec VP, General Counsel · Mar 1, 2007 – Oct 20, 2009 · Past); Kos Pharmaceuticals Inc (EVP, General Counsel · Jan 26, 2006 – Dec 13, 2006 · Past)
Director · Since at least Sep 28, 2017
Mark Iwicki
Other companies: Inhibikase Therapeutics, Inc. (Chief Executive Officer - Inhibikase · Since at least Feb 14, 2025); Q32 Bio Inc. (Director · Since at least Mar 25, 2024); Third Harmonic Bio Inc. (Director · Since at least Sep 14, 2022); Akero Therapeutics Inc (Director · Since at least Jun 19, 2019); Jade Biosciences, Inc. (Director · Apr 2, 2021 – Jun 5, 2024 · Past); Pulmatrix, Inc. (Director · Mar 20, 2017 – Jan 28, 2021 · Past); Aimmune Therapeutics Inc (Director · May 25, 2016 – Oct 10, 2020 · Past)
Director · Since at least Jul 19, 2017
Robert Langer
Other companies: Seer, Inc. (Director · Since at least Dec 3, 2020); Lyra Therapeutics, Inc. (David H. Koch Institute Professor, Massachusetts Institute of Technology · Since at least Apr 30, 2020); Korro Bio, Inc. (Director · Oct 2, 2019 – Aug 17, 2022 · Past); Moderna, Inc. (Director · Dec 7, 2018 – May 6, 2024 · Past); Rubius Therapeutics Inc (Director · Jul 17, 2018 – Oct 14, 2019 · Past); BIND Therapeutics Inc (Director · Sep 19, 2013 – Jun 21, 2016 · Past); Ocata Therapeutics Inc (Director · Oct 4, 2011 – Feb 10, 2016 · Past)
Director · Jul 19, 2017 – Jun 12, 2018 · Past
Gregory D Perry
Other companies: Novelion Therapeutics Inc (See Remarks · Nov 29, 2016 – May 9, 2017 · Past); Aegerion Pharmaceuticals Inc (See Remarks · Jul 6, 2015 – May 9, 2016 · Past); Eleven Biotherapeutics Inc (Chief Financial and Business · Feb 5, 2014 – Feb 26, 2015 · Past); InVivo Therapeutics Holdings Corp (Interim CFO · Sep 30, 2013 – Dec 30, 2013 · Past); Ocata Therapeutics Inc (Director · Dec 2, 2011 – Feb 10, 2016 · Past); ImmunoGen Inc (Chief Financial Officer · Jan 9, 2009 – Sep 10, 2013 · Past)
Director · Since at least Feb 28, 2018
Robert I Tepper
Other companies: Constellation Pharmaceuticals Inc (Director · Jul 18, 2018 – Jun 6, 2019 · Past); Allena Pharmaceuticals Inc (Director · Nov 1, 2017 – Jun 5, 2019 · Past); Jounce Therapeutics Inc (Director · Jan 26, 2017 – Jun 26, 2020 · Past); Dare Bioscience, Inc. (Director · Apr 10, 2014 – Jun 26, 2015 · Past); Bluebird bio Inc (Director · Jun 18, 2013 – Feb 3, 2015 · Past); Millennium Pharmaceuticals Inc (President, R&D · Sep 15, 2005 – Feb 12, 2007 · Past)
Director · Jul 19, 2017 – Jul 25, 2017 · Past
Mark Blumenkranz
Other companies: Annexon, Inc. (BOARD MEMBER · Since at least Aug 10, 2026); IVERIC bio Inc (Director · Jul 15, 2020 – Jul 11, 2023 · Past); 1Life Healthcare Inc (Director · Jan 30, 2020 – Feb 22, 2023 · Past); Presbia PLC (Director · Jan 28, 2015 – Mar 16, 2015 · Past); Adverum Biotechnologies Inc (Director · Jul 30, 2014 – Feb 12, 2016 · Past)
Director · Nov 15, 2021 – Jun 11, 2024 · Past
Eric Trachtenberg
Other companies: Aralez Pharmaceuticals Inc (GC, CCO & Secretary · Feb 5, 2016 – Mar 19, 2018 · Past); POZEN Inc (Deputy General Counsel · Jun 22, 2015 – Jun 22, 2015 · Past)
SEE REMARKS · Apr 2, 2018 – Jan 4, 2024 · Past
All 29 people
PersonSeat
Howard B Rosen
Other companies: Talphera, Inc. (Director · Feb 10, 2011 – Oct 10, 2023 · Past); Pharsight Corp (Director · Oct 31, 2008 – Oct 31, 2008 · Past)
Director · Since at least Jul 19, 2017
Paulina Hill
Other companies: Odyssey Therapeutics, Inc. (Director · Since at least May 7, 2026); Neuronetics, Inc. (Director · Jun 27, 2018 – Jul 2, 2018 · Past)
Director · Jul 19, 2017 – Jun 12, 2018 · Past
Todd Bazemore
Other companies: Pulmatrix, Inc. (Chief Operating Officer · Since at least Oct 1, 2020); Dyax Corp (EVP & Chief Commercial Officer · Apr 16, 2014 – Jan 22, 2016 · Past)
Director · Since at least Nov 20, 2017
C Daniel Myers
Other companies: Alimera Sciences Inc (Director · Apr 21, 2010 – Jan 4, 2023 · Past)
Director · Since at least Oct 15, 2021
Chaim D Berger
Other companies: Nova Minerals Corp (Director · Since at least Mar 17, 2026)
Director · Since at least Jan 30, 2026
Charles Douglas McDermott
Other companies: Equillium, Inc. (Director · Since at least Oct 11, 2018)
President and Chief Bus. Off. · Jul 19, 2017 – Jul 19, 2017 · Past
Gregory Grunberg
Other companies: 89bio Inc (Director · Nov 8, 2019 – Feb 9, 2023 · Past)
Director · Jul 19, 2017 – Jun 17, 2021 · Past
Romulus K Brazzell
Other companies: Inspire Pharmaceuticals Inc (EVP, Medical & Scientific · Jan 19, 2006 – May 13, 2011 · Past)
SEE REMARKS · Since at least Jul 19, 2017
Avi MinkowitzChief Executive Officer and Chief Financial Officer · Since at least Sep 29, 2026
Avraham MinkowitzChief Executive Officer, Director · Since at least Jan 30, 2026
Brendan P PurdyDirector · Since at least Jan 30, 2026
Darius KharabiCHIEF BUSINESS OFFICER · Since at least Nov 15, 2021
Hillel D PosenDirector · Since at least Jan 30, 2026
Hongming ChenCHIEF SCIENTIFIC OFFICER · Feb 7, 2018 – Oct 26, 2021 · Past
Marjan FaridDirector · Since at least Oct 31, 2022
Mary ReumuthCHIEF FINANCIAL OFFICER · Since at least Jul 19, 2017
Michele LaRussaSr. VP, Regulatory and Quality · Jul 19, 2017 – Feb 7, 2018 · Past
Robert Bradley PaullDirector · Jul 19, 2017 – Jun 16, 2022 · Past
Yonatan C ColmanDirector · Since at least Jan 30, 2026

Open People

Log in to ask 6ix AI your own questions about Kala Bio, Inc.